Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC
Aim: To evaluate real-world clinical outcomes of radium-223 or alternative novel hormonal
therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer …
therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer …
A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010–2018
DM Moldaver, S Hassan, SJ Seung, J Edwin… - … Oncology: Seminars and …, 2023 - Elsevier
Purpose We sought to quantify mCRPC patient treatment patterns and survival across
multiple lines of therapy after prior androgen-receptor-axis-targeted therapy (ARAT) failure …
multiple lines of therapy after prior androgen-receptor-axis-targeted therapy (ARAT) failure …
Systemic treatment of advanced prostate cancer
A Kretschmer, T Todenhoefer - Der Urologe, 2020 - Springer
Die systemische Therapie des fortgeschrittenen Prostatakarzinoms (PCa) erlebte in den
vergangenen Jahren tiefgreifende Veränderungen, die eine Vielzahl an neuartigen …
vergangenen Jahren tiefgreifende Veränderungen, die eine Vielzahl an neuartigen …